PET based study for early detection of inflammation and effect of treatment in psoriasis
- Conditions
- Health Condition 1: null- Patients with moderate to severe psoriasis
- Registration Number
- CTRI/2014/08/004842
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 16
PASI >5
Patients on topical or active light therapy
Patients with chronic inflammatory disease like diabetes mellitus, uncontrolled hypertension with SBP 180 mmHg and DBP 95 mmHg, cardiovascular disease and with coagulopathy
2.Patients on any systemic therapy for psoriasis like methotrexate, retinoids or biologics in preceding 6 weeks
3.Patients on tobacco, alcohol use that is 2 drinks per day or intravenous drug use.
4.Participated in a research study in preceding 6 weeks
5.Major surgery within 3 months of imaging
6.Pregnant females
7.Lactating mothers
8.Patient with liver disease
9.Blood glucose level 150 mg/dl
10.Any other inflammatory condition in the body that in the opinion of investigator may jeopardise the validity of the study or put the patients at the greater risk
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite SUV score (skin, blood vessels, liver, joints) after 12 weeks of treatment with methotrexate or placebo in patients with moderate to severe psoriasisTimepoint: Baseline (0 weeks) and 12 weeks
- Secondary Outcome Measures
Name Time Method Composite SUV score after adding pioglitazone to methotrexateTimepoint: Baseline (0 weeks) and 12 weeks;Change in level of CRP and serum homocysteine levelsTimepoint: Baseline (0 weeks) and 12 weeks;Difference from baseline in composite SUV score among treatment groupsTimepoint: Baseline (0 weeks) and 12 weeks;Effect of treatment on the individual components of SUV scoreTimepoint: Baseline (0 weeks) and 12 weeks;SUV in patients with psoriasis versus non psoriatic patientsTimepoint: Baseline in psoriasis patients and historical control